FIRST-IN-CLASS, ORAL MUTANT IDH2 INHIBITOR REVERSES DIFFERENTIATION BLOCK IN ACUTE MYELOID LEUKAEMIA TO PRODUCE CLINICALLY MEANINGFUL RESPONSES

Vyas P.

Type

Conference paper

Publication Date

2017-01-01T00:00:00+00:00

Volume

53

Pages

S38 - S38

Permalink Close